Advanced search
Publication Cover
Ocular Immunology and Inflammation Volume 9, 2001 - Issue 1
Submit an article Journal homepage
62
Views
42
CrossRef citations to date
0
Altmetric
Research Article

Use of methotrexate in the management of sight-threatening uveitis

Silvia Bom Department of Clinical Ophthalmology, Moorfields Eye Hospital, London, UK
,
Parisa Zamiri Department of Clinical Ophthalmology, Moorfields Eye Hospital, London, UK
&
Susan Lightman Department of Clinical Ophthalmology, Moorfields Eye Hospital, London, UKCorrespondence [email protected]
Pages 35-40 | Published online: 08 Jul 2009

References

  • Rothova A, Suttorp-von Shulten MS, Fritz Trefers WF, et al. Causes and frequency of blindness in patients with intra-ocular inflammatory disease. Br J Ophthalmol 1996;80:332–336.
  • Lazar M, Weiner M, Leopold I. Treatment of uveitis with methotrexate. Am J Ophthalmol 1969;3:383–387.
  • Weinstein GD, Frost P. Methotrexate for psoriasis: a new therapeutic schedule. Arch Dermatol 1971;1o3:33–38.
  • Roenig HH, Maibach HI, Weinstein G. Guidelines on methotrexate therapy for psoriasis. Arch Dermatol 1972;105:362–363.
  • Wilke WS, Biro JA, Segal AM. Methotrexate in the treatment of arthritis and connective tissue diseases. Cleveland Clin J Med 1987;54:327–338.
  • Weinblatt ME, Trentham DE, Fraser PA, et al. Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. Arthritis Rheum 1988;31:167–175.
  • Gilman AG, Goodman LS, Rall TW, Murad E The Pharmacological Basis of Therapeutics. New York: Macmillan Publishing Company, 1985;1264 p.
  • Wong VG. Methotrexate treatment of uveal disease. Am J Sci 1966; 251:239–241.
  • Shah SS, Lowder CY, Schmitt MA, et al. Low dose methotrexate therapy for ocular inflammatory disease. Ophthalmology 1992;99: 1419–1423.
  • Holz FG, Krastel H, Breitbart A, et al. Low dose methotrexate treatment in noninfectious uveitis resistant to corticosteroids. Ger J Ophthalmol 1992;1:142–144.
  • Dev S, McCallum R, Jaffe G. Methotrexate treatment, for sarcoid associated panuveitis. Ophthalmology 1999;106:H1—H8.
  • Bloch-Michel E, Nussenblatt RB. International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol 1987;103:234–235.
  • Kremer JM, Lee JK. The safety and efficacy of the use of methotrexate efficacy of the use of methotrexate in long term therapy for rheumatoid arthritis. Arthritis Rheumatol 1986;29:822–831.
  • Axehod L. Glucocorticoid therapy. Medicine (Baltimore) 1976;55:39–65.
  • Hemady R, Tauber J, Foster S. Immunosuppressive drugs in immune and inflammatory ocular disease. Surv Ophthalmol 1991; 35(5):369–385.
  • Olsen NJ, Murray LM. Antiproliferative effects of Antiproliferative effects of methotrexate on peripheral blood mononuclear cells. Arthritis Rheum 1989;32:378–385.
  • Kerwar SS, Oronsky AL. Methotrexate in rheumatoid arthritis: studies with animal models. Adv Enzyme Regul 1989;29:247–265.
  • Cronstein BN. Molecular mechanism of methotrexate action in inflammation. Inflammation 1992;16:411–423.
  • Andersen EA,West SG, O’Dell JR, et al.Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomised, double-blind study. Ann Intern Med 1985;103:489–496.
  • Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312:818–822.
  • Segal AM, Wilke WS. Toxicity of low dose methotrexate in rheumatoid arthritis. In: Wilke WS, editor. Methotrexate Therapy in Rheumatic Disease. New York: Marcel Dekker, 1989;147–178.
  • Tolman KG, Clegg DO, Lee RG, et al. Methotrexate and the liver. J Rheum 1985;12 12:29–34.
  • Kremer JM, Alancon GS, Lightfoot RW, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1997;40:2226–2234.
  • Preston SJ, Diamond T, Scott A, et al. Methotrexate osteopathy in rheumatic disease. Ann Rheum Dis 1993;52:582–585.
  • Bleyer WA. Methotrexate induced lymphoma? J Rheum 1998;25:404–407.
  • Vitale AT, Rodriguez A, Foster S. Low dose cyclosporine A therapy in treating chronic, non-infectious uveitis. Ophthalmology 1996;103:365–374.
  • Towler HM, Cliffe AM, Whiting PH, Forrester JV. Low dose cyclosporine A therapy in chronic posterior uveitis. Eye 1989;3\(pt 3):282–287.
  • Mochizuki M, Maserda K, Sakane T, et al. A clinical trial of FK-506 in refractory uveitis. Am J Ophthalmol 1993;115:763–769.
  • Andrasch RH, Pirofsky B, Burns RP. Immunosuppressive therapy for severe chronic uveitis. Arch Ophthalmol 1978;96:247–251.
  • Ishioka M, Ohno S, Nakamura S, et al. FK 506. Treatment of non-infectious uveitis. Am J Ophthalmol 1994;118:723–729.
  • Larkin G, Lightman S. Mycophenolate mofetil: a useful immunosuppressive in inflammatory eye disease. Ophthalmology 1999;106:370–374.
  • Kilmartin D, Forrester J, Dick A. Rescue therapy with mycophenolate mofetil in refractory uveitis. Lancet 1998;352:35–36.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.